RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: ANN JANSSENS

August 2021 Editor's pick Tobias Rawson

SIGNIFICANTLY IMPROVED OVERALL RESPONSE RATE WITH RUXOLITINIB IN GLUCOCORTICOID-REFRACTORY GRAFT-VERSUS-HOST DISEASE

The REACH3 phase III randomised trial evaluated ruxolitinib as compared with investigator’s choice of therapy from a list of ten commonly used options among patients with glucocorticoid-refractory or –dependent chronic graft-versus-host disease. Primary analysis demonstrates a significantly greater overall response, failure-free survival, and symptom response…

Read more

SIGNIFICANTLY HIGHER COMPLETE HAEMATOLOGICAL RESPONSE WITH DARATUMUMAB IN SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS

The phase III ANDROMEDA study evaluates the safety and efficacy of subcutaneous daratumumab plus bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light-chain (AL) amyloidosis. Primary results from the randomised portion of the trial demonstrates higher frequencies of haematologic complete response and survival free from major organ deterioration or haematologic progression… 

Read more

LONG-TERM TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA AFTER SECOND-LINE NILOTINIB

The ENESTop study evaluated treatment-free remission (TFR) in patients with chronic myeloid leukaemia (CML) in chronic phase who had received ≥3 years of tyrosine kinase inhibitor therapy and achieved sustained deep molecular response only after switching from imatinib to nilotinib. Results from a five-year update further confirm the durability and safety of TFR for patients receiving second-line nilotinib… 

Read more

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IMPROVES PFS COMPARED TO STANDARD OF CARE IN STAGE III/IV HODGKIN’S LYMPHOMA

The primary analysis of the phase III ECHELON-1 study, comparing brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in patients with stage III/IV classical Hodgkin’s lymphoma, previously reported an improvement in progression-free survival (PFS) with A+AVD. At five years, A+AVD continues to show robust and durable improvement in PFS versus ABVD, regardless of PET-2 status..

Read more

SUPERIOR SURVIVAL WITH PAEDIATRIC-STYLE CHEMOTHERAPY FOR AYA’S WITH PH-NEGATIVE ALL IN FIRST COMPLETE REMISSION

For adolescents and young adults (AYA’S) with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission, the optimal post-remission therapy remains unknown. However, an analysis from CALGB 10403 and the CIBMTR now demonstrates that post-remission therapy with paediatric-style chemotherapy is superior to myeloablative allogeneic haematopoietic stem cell transplantation for overall survival, disease-free survival and non-relapse mortality… 

Read more

X